£2.6 Million Gene Therapy for Haemophilia B Now Available on NHS

Innovative treatment offers potential long-term relief from regular injections and painful bleeds for eligible patients.

The gene therapy, Hemgenix, uses a virus to deliver functional clotting factor IX to the liver.
Elliott Collins, a trial patient, has not needed factor IX injections since 2019 and reports feeling 'cured'.
The therapy's cost-effectiveness will be monitored over a decade, with payments adjusted based on patient outcomes.
Around 250 of the 2,000 UK haemophilia B patients are expected to qualify for the treatment.
The NHS has secured this treatment under a new scheme to provide early access to pioneering drugs.